US2009203076A1PendingUtilityA1

Compositions and methods for increasing protein production

57
Assignee: KABANOV ALEXANDER VPriority: Jul 20, 2004Filed: Sep 9, 2008Published: Aug 13, 2009
Est. expiryJul 20, 2024(expired)· nominal 20-yr term from priority
C12P 21/02
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for increasing protein production are provided.

Claims

exact text as granted — not AI-modified
1 . A method for producing a protein comprising:
 a) providing cells comprising a heterologous nucleic acid encoding a recombinant protein; and   b) incubating the cells in media containing at least one amphiphilic block copolymer.   
   
   
       2 . The method of  claim 1 , comprising the further step of:
 c) replacing said media containing an amphiphilic block copolymer with media lacking said amphiphilic block copolymer.   
   
   
       3 . The method of  claim 1 , comprising the further step of isolating the expressed recombinant protein. 
   
   
       4 . The method of  claim 2 , comprising the further step of isolating the expressed recombinant protein. 
   
   
       5 . The method of  claim 1 , wherein said cells are mammalian cells. 
   
   
       6 . The method of  claim 1 , wherein said amphiphilic block copolymer comprises at least one block of poly(oxyethylene) and at least one block of poly(oxypropylene). 
   
   
       7 . The method of  claim 6 , wherein said amphiphilic block copolymer is a Pluronic® copolymer. 
   
   
       8 . The method of  claim 6 , wherein said amphiphilic block copolymer is a Tetronic® copolymer. 
   
   
       9 . The method of  claim 6 , wherein said amphiphilic block copolymer has a hydrophilic-lipophilic balance (HLB) of between 1 and 20. 
   
   
       10 . The method of  claim 9 , wherein said amphiphilic block copolymer has an HLB of between 8 and 16. 
   
   
       11 . The method of  claim 7 , wherein said Pluronic® copolymer is selected from the group consisting of Pluronic® P123, Pluronic® P103, Pluronic® P85, and Pluronic® L64. 
   
   
       12 . The method of  claim 1 , wherein said at least one amphiphilic block copolymer is a mixture of different amphiphilic block copolymers. 
   
   
       13 . The method of  claim 1 , wherein said amphiphilic block copolymer is a mixture of a Pluronic® copolymer and a polycation conjugated Pluronic® copolymer. 
   
   
       14 . The method of  claim 13 , wherein said mixture comprises Pluronic® P123 and Pluronic® P123 conjugated to polyethyleneimine. 
   
   
       15 . The method of  claim 14 , wherein the ratio of Pluronic® P123 to Pluronic(D P123 conjugated to polyethyleneimine in said mixture is 9:1 by weight. 
   
   
       16 . The method of  claim 1 , wherein said incubation of the cells in media comprising at least one amphiphilic block copolymer is for at least three hours. 
   
   
       17 . The method of  claim 16 , wherein said incubation is for at least nine hours. 
   
   
       18 . The method of  claim 6 , wherein said amphiphilic block copolymer is present in the media at a concentration ranging from about 0.0001% to about 5%. 
   
   
       19 . The method of  claim 18 , wherein said concentration ranges from about 0.1% to about 2%. 
   
   
       20 . The method of  claim 1 , wherein said heterologous nucleic acid is stably incorporated into said cells. 
   
   
       21 . The method of  claim 1 , wherein said heterologous nucleic acid encoding a recombinant protein is controlled by the cytomegalovirus promoter. 
   
   
       22 . The method of  claim 1 , wherein said recombinant protein is selected from the group consisting of cytokines, enzymes, clotting factors, vaccines, antibodies, growth factors and hormones, insulin, hemoglobin, alpha-1-antitrypsin (AAT), lactoferrin, cystic fibrosis transmembrane conductase (CFTR), human protein C, anti-viral agents, and interleukins. 
   
   
       23 . The method of  claim 22 , wherein said recombinant protein is Factor VIII and said amphiphilic block copolymer has a hydrophilic-lipophilic balance (HLB) of between 1 and 20. 
   
   
       24 . A method for producing a protein in a host comprising:
 a) providing a cell comprising a heterologous nucleic acid encoding a recombinant protein;   b) incubating the cells in media containing at least one amphiphilic block copolymer; and   c) introducing the cells into a host.   
   
   
       25 . The method of  claim 24 , wherein the cells in step a) are obtained from the host and the heterologous nucleic acid was subsequently incorporated into the cells in vitro. 
   
   
       26 . A method for enhancing production an RNA comprising:
 a) providing cells comprising a heterologous DNA encoding an RNA; and   b) incubating the cells in media containing at least one amphiphilic block copolymer.   
   
   
       27 . The method of  claim 26 , wherein said encoded for RNA is an siRNA. 
   
   
       28 . The method of  claim 26 , wherein said heterologous nucleic acid encoding a recombinant protein is controlled by the cytomegalovirus promoter or a polymerase III promoter. 
   
   
       29 . A composition comprising stably transformed cells, at least one amphiphilic block copolymer, and nucleic acid free media. 
   
   
       30 . A kit for practicing the method of  claim 1  comprising an amphiphilic block polymer, reagents to transform a cell, and at least one selection agent to isolate stably transformed cells. 
   
   
       31 . The kit of  claim 30  further comprising at least one of frozen stocks of host cells and instruction material.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.